Hormone replacement therapy and venous thromboembolism

References

• Carter C. The pill and thrombosis: epidemiological considerations. Bailliàre's Clin Obstet Gynaecol 1997; 11: 565–85
   PubMed Web of Science ®Google Scholar
• Spitzer W O, Lewis M A, Heinemann L A, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case control study. Br Med J 1996; 312: 83–8
   PubMed Web of Science ®Google Scholar
• Carter C J. Pathogenesis of thrombosis. Haemostasis and Thrombosis in Obstetrics and Gynaecology, I A Greer, A G Turpie, C D Forbes. Chapman & Hall, London 1992; 229–55
   Google Scholar
• Jick H, Derby L E, Myers M W, Vasilakis C, Newton K M. Risk of admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey M P, Hawkins M M, Carton J L, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Goldhaber S Z, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–7
   PubMed Web of Science ®Google Scholar
• Gutthann S P, Garcia Rodriguez L A, Castallsague J, Oliart A D. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997; 314: 796–800
   PubMed Web of Science ®Google Scholar
• Meade T W, Dyer S, Howarth D J, Imeson J D, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1994; 74: 77–81
   Google Scholar
• Lowe G D, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey.I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775–84
   PubMed Web of Science ®Google Scholar
• Tait R C, Walker I D, Islam S I, et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 467–80
   Google Scholar
• Tait R C, Walker I D, Islam S I, et al. Protein C activity in healthy volunteers: influence of age, sex, smoking and oral contraceptives. Thromb Haemostas 1993; 70: 281–5
   PubMed Web of Science ®Google Scholar
• Lindoff C, Peterson F, Lecander I, Martinsson G, Astedt B. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas 1996; 24: 43–50
   PubMed Web of Science ®Google Scholar
• Anonymous. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: one year double-blind placebo controlled study. The Writing Group for the Estradiol Clotting Factors Study. Thromb Haemost 1996; 75: 476–80
   PubMed Web of Science ®Google Scholar
• Lip G Y, Blann A D, Jones A F, Beevers D G. Effects of hormone replacement therapy on hemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 764–71
   PubMed Web of Science ®Google Scholar
• Koh K K, Mincemoyer R, Bui M N, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683–90
   PubMed Web of Science ®Google Scholar
• Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing prostagen components. Lancet 1995; 346: 1589–93
   PubMed Web of Science ®Google Scholar
• Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. PEPI (The Postmenopausal Estrogen/Progestin Interventions Trial) Writing Group. J Am Med Assoc 1995; 273: 199–208
   PubMed Web of Science ®Google Scholar
• Walker I D. Congenital thrombophilia. Bailliàres Clin Obstet Gynaecol 1997; 11: 431–45
   PubMed Web of Science ®Google Scholar
• Dahlback B, Hillarp A, Rosen S, Zoller B. Resistance to activated protein C, the FV:Q506 allele and venous thrombosis. Ann Hematol 1996; 72: 166–76
   PubMed Web of Science ®Google Scholar
• Zoller B, Holm J, Dahlback B. Resistance to activated protein C due to a factor V gene mutation: the most common inherited risk factor of thrombosis. Trends Cardiovasc Med 1996; 6: 45–53
   PubMed Web of Science ®Google Scholar
• Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: A new mutation (Arg306 Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140–4
   PubMed Web of Science ®Google Scholar
• Poort S R, Rosendall F R, Reitsma P H, Bertina R M. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–703
   PubMed Web of Science ®Google Scholar
• Van der Mooren M J, Wouters M G, Blom H J, Schellekens L A, Eskes T K, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in post-menopausal women. Eur J Clin Invest 1994; 24: 733–6
   PubMed Web of Science ®Google Scholar
• Hellgren M, Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210–13
   PubMed Web of Science ®Google Scholar
• Bertina R M, Koeleman B P, Koster T, et al. Mutation in blood coagulation factor V association with resistance to activated protein C. Nature 1994; 369: 64–7
   PubMed Web of Science ®Google Scholar
• Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 567–74
   PubMed Web of Science ®Google Scholar
• Whitehead M, Godfree V. Venous thromboembolism and hormone replacement therapy. Bailliàres Clin Obstet Gynaecol 1997; 11: 587–99
   PubMed Web of Science ®Google Scholar
• Greer I A. Practical strategies for hormone replacement therapy and risk of venous thromboembolism. Br J Obstet Gynaecol 1998; 105: 376–9
   PubMedGoogle Scholar
• Greer I A. Epidemiology risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology. Bailliàres Clin Obstet Gynaecol 1997; 11: 403–30
   PubMed Web of Science ®Google Scholar